Truist raised the firm’s price target on Praxis Precision (PRAX) to $360 from $85 and keeps a Buy rating on the shares after the company reported topline results of Study 1 and 2 from the ESSENTIAL3 trial of ulixacaltamide in essential tremor that the firm called “impressive across the board.” The firm, which reintroduces ET in its sum-of-the-parts value, says it derives its increased price target “even with conservative assumptions.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $275 from $76 at Baird
- Midday Fly By: Salesforce targets $60B in revenue, TSMC reports Q3 beat
- Buy Rating Affirmed for Praxis Precision Medicines Following Positive Phase 3 Study Results
- Praxis Precision price target raised to $300 from $65 at Jefferies
- Praxis Precision price target raised to $350 from $155 at Guggenheim